C3 glomerulopathy Advocacy Hub | UniteRare

At a Glance

Live from database

💊

Regulatory Watchboard

10 events

Feb 2026Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study

Novartis Pharmaceuticals

TrialNOT YET RECRUITING

Jan 2026CHART-C3G/CLNP023B12011

Novartis Pharmaceuticals

TrialNOT YET RECRUITING

Nov 2025Study of NM8074 in Adult C3 Glomerulopathy Patients

NovelMed Therapeutics — PHASE1, PHASE2

TrialNOT YET RECRUITING

Oct 2025Predictive Value of a Rectal Swab With Detection of Enterobacteria (ESBL-E), Carbapenemases, and High-level Cephalosporinase (HLC) on the Risk of Infections With C3G-resistant Enterobacteria

University Hospital, Strasbourg, France

TrialRECRUITING

Sep 2025Fabhalta Capsules Specified Drug-use Survey

Novartis Pharmaceuticals

TrialRECRUITING

Jun 2025A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

eleva GmbH — PHASE1

TrialRECRUITING

Apr 2025Home Reported Outcomes in C3G Study

Novartis Pharmaceuticals

TrialRECRUITING

Mar 2025

FABHALTA: FDA approved

treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria

FDAcompleted

Mar 2025Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

Kira Pharmacenticals (US), LLC. — PHASE2

TrialNOT YET RECRUITING

Jul 2021Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Novartis Pharmaceuticals — PHASE3

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs2

Empaveli

Apellis Pharmaceuticals, Inc.

OpenContact for detailsApply ↗

FABHALTA

Novartis Pharmaceuticals Corporation

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

2 FDA-approved

Empaveli

(PEGCETACOPLAN)Orphan drugsNDA

Apellis Pharmaceuticals, Inc.

Approved Jul 2025FDA label ↗

FABHALTA

(IPTACOPAN)Orphan drug

Novartis Pharmaceuticals Corporation

Approved Mar 2025FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

4 active trials

1Phase 3

1Phase 1

2Unknown

4Total recruiting

Search clinical trials for C3 glomerulopathy →

Recent News & Research

No recent news articles indexed yet for C3 glomerulopathy.
Search PubMed for C3 glomerulopathy →

Browse all C3 glomerulopathy news →

Specialist Network

Top 6 by expertise

Fernando C Fervenza, MD, M.D

Mayo Clinic

📍 ROCHESTER, MN

Score 211 trial

Diana Karpman

Region Skåne

Score 81 trial8 pubs

Steve Whitaker, MD

Omeros Corporation

Score 83 trials

Bernd Jilma, Prof.

Medical University of Vienna

Score 41 trial

Edwin K S Wong

Translational and Clinical Research Institute

Score 02 pubs

Yaqin Wang

Novartis Pharmaceutical Corporation

Score 03 pubs

View all C3 glomerulopathy specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰